Source:http://linkedlifedata.com/resource/pubmed/id/11146161
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2001-1-10
|
pubmed:abstractText |
In this study, the utility of DT388-granulocyte-macrophage colony-stimulating factor (GM-CSF) for the ex vivo purging and direct administration to patients with acute myeloid leukemia (AML) is tested using clonogenic assays, long-term cultures (LTC), and NOD/SCID mice as assays for leukemic progenitors. We compare the ability of 24-hour exposure to 0.3 microg/mL (4 nM) DT388-GM-CSF to kill AML colony forming cells (CFC) and the more primitive AML progenitors detected after 6 weeks in stromal cocultures (AML LTC-initiating cells or AML LTC-IC) and after 8 weeks in NOD/SCID mice.AML samples (n = 10), expressing a mean of 35 to 1466 GM-CSF receptors/blast, showed mean (range) percent kills of AML CFC and LTC-IC of 61 (17-98) and 46 (0-94) respectively with a direct correlation (r = 0.69) between the % kills detected in the in vitro assays. Among 5 evaluable samples the percent reduction in AML cell engraftment in NOD/SCID marrow following ex vivo DT388-GM-CSF treatment varied from 38% to 100%. 40% to 56% of normal bone marrow CFC and 31% to 48% of normal LTC-IC survived the same ex vivo treatment (n = 3). In subsequent experiments, NOD/SCID mice received AML blast cell injections intravenously followed in 24 hours by 1.5 microg DT388-GM-CSF daily intraperitoneally for 5 days. A reduction of marrow blast cells was seen with 7 of 9 samples tested 4 to 12 weeks post one course of toxin. Repeating the 5-day course of toxin 2 or 3 times at 4-week intervals did not improve the response, while delaying administration until 4 to 8 weeks post AML cell injection reduced the toxin's effectiveness (n = 5).This fusion toxin may prove useful for in vitro purging of stem cell harvests from selected AML patients and for direct administration to such patients.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Diphtheria Toxin,
http://linkedlifedata.com/resource/pubmed/chemical/Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Granulocyte-Macrophage...,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0301-472X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
28
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1390-400
|
pubmed:dateRevised |
2009-11-3
|
pubmed:meshHeading |
pubmed-meshheading:11146161-Animals,
pubmed-meshheading:11146161-Bone Marrow,
pubmed-meshheading:11146161-Bone Marrow Purging,
pubmed-meshheading:11146161-Cell Death,
pubmed-meshheading:11146161-Cytogenetic Analysis,
pubmed-meshheading:11146161-Diphtheria Toxin,
pubmed-meshheading:11146161-Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:11146161-Hematopoietic Stem Cells,
pubmed-meshheading:11146161-Humans,
pubmed-meshheading:11146161-In Situ Hybridization, Fluorescence,
pubmed-meshheading:11146161-Leukemia, Myeloid, Acute,
pubmed-meshheading:11146161-Mice,
pubmed-meshheading:11146161-Mice, Inbred NOD,
pubmed-meshheading:11146161-Mice, SCID,
pubmed-meshheading:11146161-Neoplasm Transplantation,
pubmed-meshheading:11146161-Receptors, Granulocyte-Macrophage Colony-Stimulating Factor,
pubmed-meshheading:11146161-Recombinant Fusion Proteins,
pubmed-meshheading:11146161-Spleen,
pubmed-meshheading:11146161-Tumor Cells, Cultured
|
pubmed:year |
2000
|
pubmed:articleTitle |
Variable cytotoxicity of diphtheria toxin 388-granulocyte-macrophage colony-stimulating factor fusion protein for acute myelogenous leukemia stem cells.
|
pubmed:affiliation |
Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|